Open AccessDirect‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
Author(s) -
Toyoda Hidenori
Publication year - 2019
Publication title -
health science reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 7
ISSN - 2398-8835
DOI - 10.1002/hsr2.106
Subject(s) - ribavirin , regimen , ombitasvir , ritonavir , paritaprevir , medicine , genotype , hepatitis c virus , virology , chronic hepatitis , cirrhosis , dasabuvir , antiviral therapy , hepatitis c , virus , viral load , biology , antiretroviral therapy , biochemistry , gene
The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.